Drug Profile
PLX 3623
Alternative Names: PLX-3623Latest Information Update: 07 Jul 2022
Price :
$50
*
At a glance
- Originator Plexxikon
- Class Antineoplastics
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 31 Mar 2022 Plexxikon (a subsidiary of Daiichi Sankyo) closes its office and research facility permanently (Plexxikon website, July 2022)
- 31 Mar 2022 Discontinued - Preclinical for Cancer in USA (Parenteral)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)